2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2050

B and T Cell Phenotypes of First Degree Relatives of RA Patients in an Indigenous North American Cohort
Abstract Number: 1561

B Lymphocyte Depletion Therapy with Rituximab in Primary Sjögren’s Syndrome: Indications , Effectiveness and Ultrasonographic Response
Abstract Number: 180

Back to Bedside Teaching: Completion of a Rheumatology Rotation Significantly Increases Internal Medicine Residents’ Competency and Comfort with Comprehensive Knee Examinations
Abstract Number: 65

Bacteria-Derived Indole Drives Autoimmune Arthritis By Altering B Cell Glycosylation of Autoantibodies
Abstract Number: 2124

Bacterial Biofilm Product Curli/Edna Induces NETs and Serum Anti-Curli/Edna Levels Correlate with Bacteriuria and Lupus Activity
Abstract Number: 111

BAFF Inhibition Attenuates Fibrosis in Bleomycin-Induced Scleroderma Model Via Modulating the Regulatory and Effector B-Cell Balance
Abstract Number: 1908

Bariatric Surgery Does Not Affect the Incidence of Rheumatoid Arthritis in Obese Subjects
Abstract Number: 1518

Baricitinib and Tofacitinib in Real Life – Does Obesity Impact Response to Janus Kinase Inhibitor Therapy in Rheumatoid Arthritis?
Abstract Number: 970

Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Abstract Number: 1894

Baricitinib-Associated Changes in Type l Interferon Gene Signature during a 24-Week Phase-2 Clinical SLE Trial
Abstract Number: 546

Baricitinib: Early Vs. Delayed Start in Patients with Rheumatoid Arthritis
Abstract Number: 1526

Baseline Characteristics and Outcomes in Patients with Anemia in Clinical Studies of Tofacitinib
Abstract Number: 1495

Baseline Characteristics of Methotrexate Inadequate Responder Patients with RA Who Achieved Low Disease Activity with Tofacitinib Monotherapy
Abstract Number: 468

Baseline Features and Outcomes of Pediatric-Onset Discoid Lupus Erythematosus: Interim Data Analysis of a Multicenter Retrospective Cohort Study
Abstract Number: 2588

Baseline Pain Severity As a Predictor of Pain Improvement Following Treatment with Tofacitinib in Psoriatic Arthritis
Abstract Number: 582

Baseline Power Doppler and Multi-Biomarker Disease Activity Score Predict 12-Week Disease Activity Response to Tofacitinib
Abstract Number: 847

Basic Calcium Phosphate Crystals Induce Osteoarthritis-Associated Changes in Chondrocyte Phenotype through Activation of Calcium/Calmodulin Kinase 2
Abstract Number: 280

Be Fierce. Take Control.TM an Evidence-Based Digital Lupus Awareness and Education Campaign for Young Minority Women at Risk for Lupus
Abstract Number: 1802

Behcet’s Disease in the Southwestern United States
Abstract Number: 1975

Behcet’s Disease Lies in the “B” Holder. New Associations in Disease Susceptibility and Manifestations
Abstract Number: 1948

Beliefs and Preferences for Reducing Sedentary Time in Those with Current or Past Knee Symptoms
Abstract Number: 2072

Beneficial Effect of Combination Therapy of Etanercept with Non-Steroidal Anti-Inflammatory Drugs Compared to Etanercept Monotherapy in a Spondyloarthritis Animal Model
Abstract Number: 2537

Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)
Abstract Number: 283

Benefits Accrued through the Implementation of Telerheumatology Services
Abstract Number: 2511

Benepali Switches in Clinical Practice – a Positive Single Centre Experience
Abstract Number: 240

Bi-Directional Associations between “Too Much Sitting” and Self-Reported Pain in Patients with Rheumatoid Arthritis
Abstract Number: 1915

Big Data Analysis of Autoimmune Diseases Induced By Cancer Immunotherapies: Identifying Pharmacological Patterns of Organ-Specific Involvement
Abstract Number: 550

Biologic Discontinuation in Rheumatoid Arthritis: A Population Based Study 1999-2017
Abstract Number: 2866

Biologic Refractory Disease in a Cohort Study of Children and Young People with Juvenile Idiopathic Arthritis from the United Kingdom
Abstract Number: 93

Biomarkers Associating Endothelial Function in Systemic Lupus Erythematous
Abstract Number: 957

Biomechanical Therapy for Osteoarthritis of the Knee: A Randomized Controlled Trial
Abstract Number: 2522

Biosimilar BI 695501 and Adalimumab Reference Product (RP) Have Similar Efficacy and Safety in Patients (pts) with Moderately-to-Severely Active Rheumatoid Arthritis (RA): Long-Term Results from a Phase IIIb Extension Study (VOLTAIRE®-RAext)
Abstract Number: 2154

Biosimilar Infliximab Treated-Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in France: Characteristics and Clinical Outcomes
Abstract Number: 2384

Biosimilar Use in Young Adults with Juvenile Idiopathic Arthritis in Germany
Abstract Number: 2431

Birth Outcomes and Disease Activity during Pregnancy in a Prospective Cohort of Women with Psoriatic Arthritis and Ankylosing Spondylitis
Abstract Number: 2423

Births to Women with Systemic Lupus Erythematosus Can be Identified Accurately in the Electronic Health Record
Abstract Number: 2424

Bisphosphonates during Pregnancy: A Systematic Review Sayanika Kaur MD Fellow Drexel Rheumatology, Mojdeh Khaamesi MD Resident Internal Medicine Arundathi Jayatilleke MD Program Director Drexel Rheumatology
Abstract Number: 2065

Blockade of the JAK/STAT Pathway Inhibits Inflammation and Bone Formation in Two Murine Models of Spondyloarthritis
Abstract Number: 618

Blood Lymphocytes Subtypes As Biomarkers for Early Identification of Optimal Responders to Anti-TNF Treatment in Rheumatoid Arthritis
Abstract Number: 2377

Body Image in Rheumatic Diseases: A Systematic Review
Abstract Number: 2399

Bone Density, Structure and Strength in Canadian Children and Youth with Juvenile Idiopathic Arthritis: The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)
Abstract Number: 1459

Bone Erosion Volume Changes Measured By HR-pQCT at 3-Months after Initiation of Anti-TNF Treatment Predicted Erosion Volume Changes at 1-Year in RA
Abstract Number: 485

Bone Loss in Different Sites over Time in Patients with Rheumatoid Arthritis
Abstract Number: 1597

Bone Mineral Density and Serum Biomarkers of Bone Turnover in Ankylosing Spondylitis Patients Treated with Secukinumab: 2-Year Data from the Pivotal Phase 3 Study
Abstract Number: 956

Bone Mineral Density Is a Causal Risk Factor for Knee and Hip Osteoarthritis: A Population-Based and Mendelian Randomization Study in the UK Biobank
Abstract Number: 2639

Bone Mineral Density Is Not Associated with Osteoporotic Fractures in Premenopausal Women and Men < 50 Years Old with Systemic Lupus Erythematosus
Abstract Number: 2259

BONE Sarcoidosis: A French Case Control Study
Abstract Number: 2701

Botulinum Toxin in the Management of Raynaud’s Phenomenon
Abstract Number: 661

Bridging the Gap between Symptom Onset and Diagnosis in Axial Spondyloarthritis
Abstract Number: 526

Bronchiectasis in RA Is a Crucial Risk Factor of Hospitalised Pneumonia Associated with Bdmards As Well As Interstitial Lung Disease
Abstract Number: 2099

Bruton’s Tyrosine Kinase (BTK) Inhibition Modulates Multiple Cell Types Instrumental in the Pathogenesis of Lupus Nephritis
Abstract Number: 2173

Budget Impact of Etanercept Versus Adalimumab for Treatment of Rheumatoid Arthritis in Biologic-Naïve Patients in the United Kingdom
Abstract Number: 300

Built-in-Electronic-Medical-Record Disease Activity Calculators and Treat-to-Target in Rheumatoid Arthritis
Abstract Number: 1755

Burden of Illness Associated with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States
Abstract Number: 288

Burden of Illness of Treating Patients with Pemphigus vulgaris

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].